Table 7. Phase I/II studies of non-platinum doublets in advanced NSCLC (10).
Regimen | Studies (n) | Assessable patients (n) | RR (%) range AR | MS (months) | IYS (%) | |
---|---|---|---|---|---|---|
Gem/VNR | 6 | 286 | 19-73 | 41 | 9,12 | NR |
Doc/VNR | 6 | 174 | 20-88 | 48 | 5,9 | 24 |
Pac/Gem | 3 | 117 | 30-35 | 33 | NR | NR |
Doc/Gem | 2 | 73 | 38-39 | 13 | 51 | |
Doc/CPT-11 | 1 | 32 | 34 | 9,8 | 38 | |
Pac/VNR | 1 | 25 | 16 | NR | NR | |
Gem/Topotecan | 1 | 13 | 30 | NR | NR |